US2007066538A1PendingUtilityA1

Treatment of wounds

Assignee: SECR DEFENCEPriority: Oct 22, 1999Filed: Aug 31, 2006Published: Mar 22, 2007
Est. expiryOct 22, 2019(expired)· nominal 20-yr term from priority
Inventors:David Pritchard
A61K 38/00A61L 15/32C07K 14/43577
58
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

An isolated protein, for use in treatment of wounds, is characterized in that it is secreted by the organism Lucilia sericata and it exhibits proteolytic activity against FITC-casein at a pH of 8.0 to 8.5. The protein exhibits proteolytic activity against Tosyl-Gly-Pro-Arg-AMC but not against Suc-Ala-Ala-Phe-AMC, and its proteolytic activity against FITC-casein and Tosyl-Gly-Pro-Arg-AMC is inhibited by the serine proteinase inhibitors PMSF and AMPSF. The protein is also bound by immobilized aminobenzamidine.

Claims

exact text as granted — not AI-modified
1 . (canceled)  
     
     
         2 . The method of  claim 6 , wherein the isolated protein has a molecular weight of approximately 25 kDa.  
     
     
         3 . (canceled)  
     
     
         4 . The method of  claim 6 , wherein the isolated protein is secreted by an insect in its larval stage.  
     
     
         5 . (canceled)  
     
     
         6 . A method for treating a wound to promote healing thereof in a human or non-human mammal, which comprises applying to the wound a therapeutically effective amount of: 
 (a) an isolated protein characterized in that: 
 i) it is secreted by the organism  Lucilia sericata;    
 ii) it exhibits optimum proteolytic activity against FITC-casein at a pH of 8.0 to 8.5;  
 iii) it exhibits proteolytic activity against Tosyl-Gly-Pro-Arg-AMC but not against Suc-Ala-Ala-Phe-AMC;  
 iv) its proteolytic activity against FITC-casein and Tosyl-Gly-Pro-Arg-AMC is inhibited by the serine proteinase inhibitors PMSF and APMSF; and  
 v) it is bound by immobilized aminobenzamidine; or  
   (b) one or more peptides selected from the group consisting of Ser-Phe-Leu-Leu-Arg-Asn (SEQ ID NO: 1); Ser-Leu-Ile-Gly-Lys-Val (SEQ ID NO: 2); Thr-Phe-Arg-Gly-Ala-Pro (SEQ ID NO: 3); Gly-Tyr-Pro-Gly-Gln-Val ((SEQ ID NO: 4); a peptide having as an N-terminal sequence Ser-Phe-Leu-Leu-Arg-Asn (SEQ ID NO: 1), Ser-Leu-Ile-Gly-Lys-Val (SEQ ID NO: 2), Thr-Phe-Arg-Gly-Ala-Pro (SEQ ID NO: 3), or Gly-Tyr-Pro-Gly-Gln-Val (SEQ ID NO: 4); and analogues thereof which are protected against aminopeptidase activity.    
     
     
         7 . The method of  claim 6  wherein the isolated protein or peptide is applied as a sterile composition comprising a therapeutically effective amount of the isolated protein or peptide and a sterile carrier therefore.  
     
     
         8 . (canceled)  
     
     
         9 . (canceled)  
     
     
         10 . An isolated peptide selected from the group consisting of 
 Ser-Phe-Leu-Leu-Arg-Asn (SEQ ID NO: 1); Ser-Leu-Ile-Gly-Lys-Val (SEQ ID NO: 2); Thr-Phe-Arg-Gly-Ala-Pro (SEQ ID NO: 3); Gly-Tyr-Pro-Gly-Gln-Val (SEQ ID NO: 4); a peptide having as an N-terminal sequence Ser-Phe-Leu-Leu-Arg-Asn (SEQ ID NO: 2), Ser-Leu-Ile-Gly-Lys-Val (SEQ ID NO: 2), Thr-Phe-Arg-Gly-Ala-Pro (SEQ ID NO:3), or Gly-Tyr-Pro-Gly-Gln-Val (SEQ ID NO: 4); and analogues thereof which are protected against aminopeptidase activity    
     
     
         11 . (canceled)  
     
     
         12 . (canceled)  
     
     
         13 . A dressing for a wound, which comprises a sterile support and isolated protein characterised in that: 
 i) it is secreted by the organism  Lucilia sericata;      ii) it exhibits optimum proteolytic activity against FITC-casein at a pH of 8.0 to 8.5;    iii) it exhibits proteolytic activity against Tosyl-Gly-Pro-Arg-AMC but not against Suc-Ala-Ala-Phe-AMC;    iv) its proteolytic activity against FITC-casein and Tosyl-Gly-Pro-Arg-AMC is inhibited by the serine proteinase inhibitors PMSF and APMSF; and    v) it is bound by immobilised aminobenzamidine.    
     
     
         14 . A dressing for a wound, which comprises a sterile support and at least one peptide according to  claim 10 .  
     
     
         15 . A protein which is protected against aminopeptidase activity, wherein the protein is characterized in that: 
 i) it is secreted by the organism  Lucilia sericata;      ii) it exhibits optimum proteolytic activity against FITC-casein at a pH of 8.0 to 8.5;    iii) it exhibits proteolytic activity against Tosyl-Gly-Pro-Arg-AMC but not against Suc-Ala-Ala-Phe-AMC;    iv) its proteolytic activity against FITC-casein and Tosyl-Gly-Pro-Arg-AMC is inhibited by the serine proteinase inhibitors PMSF and APMSF; and    v) it is bound by immobilized aminobenzamidine.    
     
     
         16 . A protein which is protected against aminopeptidase activity, wherein the protein comprises at least one peptide according to  claim 10 .  
     
     
         17 . The protein of  claim 15  wherein protection against aminopeptidase activity is achieved by amidation at the COOH substitution in the protein using a non-coded anomalous amino acid.  
     
     
         18 . The protein of  claim 15  wherein protection against aminopeptidase activity is achieved by replacing a CO—NH bond by an isostere.  
     
     
         19 . The protein of  claim 15  wherein protection against aminopeptidase activity is achieved by amidation at the COOH substitution in the protein using a non-coded anomalous amino acid and by replacing a CO—NH bond by an isostere.  
     
     
         20 . A composition for the treatment of wounds comprising a therapeutically effective amount of a protein according to  claim 6  and a sterile carrier therefore.  
     
     
         21 . The composition of  claim 20  further comprising a material capable of delivering the protein to a wound in a slow release or controlled release manner.  
     
     
         22 . The composition of  claim 21  wherein the material is poly(lactide-co-glycolide) or particles of PLGA.  
     
     
         23 . The composition of  claim 20  wherein the protein is protected against aminopeptidase activity.  
     
     
         24 . The dressing of  claim 13  wherein the protein is protected against aminopeptidase activity.  
     
     
         25 . The dressing of  claim 13  further comprising slow-release colloidal particles.  
     
     
         26 . The dressing of  claim 13  further comprising sponges.  
     
     
         27 . The dressing of  claim 13  which is over layered by a conventional dressing.

Join the waitlist — get patent alerts

Track US2007066538A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.